This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Power for Ancient Names in Biotech

Stocks in this article: GILD ISIS AEGR

Their flagship product, Kynamro, is an apo-B synthesis inhibitor in development for the reduction of low-density lipoprotein cholesterol. The company has collaboration agreements with Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy. It's also working with Bristol-Myers Squibb (BMY) to discover, develop, and commercialize antisense drugs targeting proprotein convertase subtilisin/kexin type 9; and Ortho-McNeil-Janssen Pharmaceuticals to discover, develop and commercialize antisense drugs to treat metabolic diseases, including type 2 diabetes.

Isis also has a strategic relationship with Eli Lilly (LLY) for the development of LY2181308, an antisense inhibitor of surviving as well as a strategic alliance with GlaxoSmithKline (GSK) to develop new drugs against targets for rare and serious diseases. These valuable collaborations and strategic relationships put the Carlsbad, Calif.-headquartered Isis on the radar screen of the "Smart Money" and a large number of savvy investors.

There's one big possible "fly-in-the-ointment" so to speak. Another biopharmaceutical named Aegerion Pharmaceutical (AEGR - Get Report) has a similar cholesterol-fighting drug that the FDA is about to anoint as "safe and effective."

On Monday Oct. 15 (a busy day in the world of medical drugs and companies) an FDC regulatory staff report expressed its support of a possible approval of a plan that manages the risks of AEGR's drug, Lomitapide. It combats the most life-threatening forms of extremely high cholesterol levels. An advisory panel will meet Oct. 17 on the drug, which is Aegerion's most promising product candidate, with the FDA scheduled to make a final decision by the end of December.

AEGR shares were up an astounding 12.4% on Monday hitting a new 52-week high of $18.15. ISIS shares rose as well, up as high as $14 intra-day before cooling down after the good news on AEGR's drug.

The chart below compares the 1-year price gains of both ISIS and AEGR to colorfully illustrate how hot the biopharmaceutical sector has been. Biotech and biopharma stocks are in the mid stages of a long-awaited bull market.

ISIS Chart ISIS data by YCharts

Careful investors might want to start nibbling on GILD, ISIS and AEGR on any pullbacks in anticipation of more possible good news about their blockbuster medicines and their potentially life-saving array of yet-to-be-approved products. Accumulate carefully and as Jim Cramer likes to admonish, use limit orders. These kinds of stocks are very volatile.

At of the time of publication the author held no positions in any of the companies mentioned in this article.

Jim Cramer and Stephanie Link actively manage a real money portfolio for his charitable trust- enjoy advance notice of every trade, full access to the portfolio, and deep coverage of the latest economic events and market movements.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs